Oncology-focused CRO formed
International, have joined to forces to specialise in the area of
oncology services.
The combined company, called Averion International, now has the expertise of Dr Gene Resnick from IT&E, a clinical oncologist with over 25 years experience in oncology clinical practice and specialised CRO leadership, as well as that of Dr Phil Lavin from Averion, a statistician and strategist with over 20 years experience in oncology clinical trial designs.
"Other CROs offer services in the oncology field, however, our unique experience in biomarkers, haematological cancers and solid tumours puts us in a unique position in the industry," Dr Phil Lavin, CEO of Averion International told Outsourcing-Pharma.com.
"In addition, by joining together we are now able to offer an expanded service range, working with clients from the early drug testing stage, right through to commercialisation."
IT&E has a particular specialty in process and system validation, including creation of cleanrooms and standard operating procedures (SOPs), as well as ensuring manufacturing quality control and regulatory compliance.
Averion offers full-phase clinical trial management services, including site monitoring, data management and biometrics as well as FDA and product registration support, pharmacovigilance and medical writing.
"Now we can begin building relationships with clients at an earlier stage than before and continue building upon relationship this as the drug progresses," said Lavin.
Since the merger, Averion International - which also specialises in the areas of nephrology, dermatology, and medical devices - now has 250 employees in offices located in Boston, New York, San Francisco, San Diego and in Darmstadt, Germany, as well as operations in Poland, Russia and Belarus - set up to find fresh supplies of patients for clinical trials.
Looking forward, Lavin said: "We are setting ambitious goals for the new company and have a solid foundation in place from which to build upon."
"We plan to carry out an aggressive acquisition program over the next 2-3 years and will be looking particularly at expanding into Eastern Europe."
